Molecular Cancer Therapeutics · 2016 · 54 citations · 38 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyTumor ProgressionCancer ProgressionCellular Responses To HypoxiaHypoxia AdaptationMelanoma PharmacotherapyHypoxia-driven Therapy ResistanceHypoxia-induced ResistanceHypoxia-mediated ResistanceHypoxic HeterogeneityHypoxic MicroenvironmentSpheroid CultureSpheroid Culture ModelsSpheroid Models
Melanoma is molecularly and structurally heterogeneous, with some tumor cells existing under hypoxic conditions. Our cell growth assays showed that under controlled hypoxic conditions, BRAF(V600E) melanoma cells rapidly became resistant to vemurafenib. By employing both a three-dimensional (3D) spheroid model and a two-dimensional (2D) hypoxic culture system to model hypoxia in vivo, we identified upregulation of HGF/MET signaling as a major mechanism associated with vemurafenib resistance as compared with 2D standard tissue culture in ambient air. We further confirmed that the upregulation of HGF/MET signaling was evident in drug-resistant melanoma patient tissues and mouse xenografts. Pharmacologic inhibition of the c-Met/Akt pathway restored the sensitivity of melanoma spheroids or 2D hypoxic cultures to vemurafenib. Mol Cancer Ther; 15(10); 2442-54. ©2016 AACR.
38
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations
Medicine, Oncology, Pharmacology +15
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations
Medicine, Oncology, Pharmacology +17
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian, Hubing Shi, Qi Wang et al. · Nature · 2010 · 2.2K citations
Medicine, Cancer Biology, Oncology +11